Neurology | Phase I/ Phase II Developments

Stoke Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

The Beverage Forum 2021

Participation Not Confirmed

Update your events

Stoke Therapeutics To Start Dravet Syndrome Therapy Trial in UK

Lead Product(s): STK-001

Therapeutic Area: Neurology Product Name: STK-001

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2021

Details:

Stoke Therapeutics is set to commence a Phase I/IIa ADMIRAL study of its investigational new medicine, STK-001. STK-001, a proprietary antisense oligonucleotide, has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome.

Kadimastem

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

The Beverage Forum 2021

Participation Not Confirmed

Update your events

Kadimastem Granted a Patent in Israel for the Treatment of ALS

Lead Product(s): Human pluripotent stem cells

Therapeutic Area: Neurology Product Name: AstroRx

Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 09, 2021

Details:

Kadimastem’s flagship product, AstroRx®, is comprised of a differentiated cell population of human astrocytes derived from human pluripotent stem cells and is in clinical development as a therapeutic treatment for ALS.

AC Immune

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

The Beverage Forum 2021

Participation Not Confirmed

Update your events

AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study

Lead Product(s): ACI-35.030

Therapeutic Area: Neurology Product Name: ACI-35.030

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 11, 2021

Details:

Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer’s disease.